Gemigliptin, metformin combo beats monotherapy in T2DM

Gemigliptin, metformin combo beats monotherapy in T2DM

(HealthDay)—Gemigliptin combined with metformin is superior to monotherapy with either drug for patients with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 13 in Diabetes, Obesity and Metabolism.

Soo Lim, M.D., Ph.D., from the Seoul National University College of Medicine in South Korea, and colleagues randomized 433 patients with T2DM with a glycosylated hemoglobin (HbA1c) level of 7.5 to 11.0 percent and fasting plasma glucose concentration <270 mg/dL to receive either gemigliptin plus metformin, gemigliptin alone, or metformin alone. The change in HbA1c at 24 weeks was assessed as the primary end point.

The researchers found that from baseline to week 24 the mean changes in HbA1c were −2.06 percent, −1.24 percent, and −1.47 percent, respectively, in the combination, gemigliptin monotherapy, and metformin monotherapy groups, respectively. For between-group differences in HbA1c changes, the 95 percent confidence intervals were −1.02 to −0.63 for the combination group versus the gemigliptin group, and −0.82 to −0.41 for the combination group versus the metformin group. Compared with the monotherapy groups, the percentage of patients in the combination therapy group that reached the target HbA1c level <7 percent (or <6.5 percent) was significantly higher. There were no reports of serious side effects.

"In T2DM patients, the initial combination of gemigliptin and had superior efficacy without safety concerns compared with monotherapy with either drug," the authors write.


Explore further

Ranolazine added to glimepiride cuts HbA1c in T2DM

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Gemigliptin, metformin combo beats monotherapy in T2DM (2016, September 20) retrieved 20 August 2019 from https://medicalxpress.com/news/2016-09-gemigliptin-metformin-combo-monotherapy-t2dm.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more